Brian Abrahams
Stock Analyst at RBC Capital
(2.35)
# 2,362
Out of 5,182 analysts
455
Total ratings
41.96%
Success rate
-0.27%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DMRA Damora Therapeutics | Initiates: Outperform | $40 | $25.50 | +56.86% | 1 | Apr 24, 2026 | |
| EVMN Evommune | Reiterates: Outperform | $48 | $25.00 | +92.00% | 1 | Apr 10, 2026 | |
| PHVS Pharvaris | Maintains: Outperform | $52 → $51 | $28.71 | +77.64% | 2 | Apr 6, 2026 | |
| APGE Apogee Therapeutics | Maintains: Sector Perform | $83 → $82 | $86.49 | -5.19% | 4 | Mar 3, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $745 → $765 | $744.44 | +2.76% | 36 | Mar 2, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Sector Perform | $12 → $13 | $16.85 | -22.85% | 5 | Mar 2, 2026 | |
| AARD Aardvark Therapeutics | Downgrades: Sector Perform | $18 → $6 | $5.52 | +8.70% | 6 | Mar 2, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $31 → $30 | $22.30 | +34.53% | 5 | Feb 26, 2026 | |
| GLPG Galapagos NV | Maintains: Sector Perform | $32 → $33 | $28.55 | +15.59% | 14 | Feb 25, 2026 | |
| PRTA Prothena Corporation | Maintains: Sector Perform | $11 → $12 | $10.79 | +11.21% | 13 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $87 → $82 | $69.22 | +18.46% | 24 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $546 → $541 | $426.01 | +26.99% | 58 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $177 | $128.04 | +38.24% | 25 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $95 → $92 | $95.72 | -3.88% | 25 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $103 → $118 | $127.75 | -7.63% | 35 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $217 → $233 | $180.67 | +28.96% | 42 | Feb 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $13 | $8.90 | +46.07% | 20 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $30 | $16.49 | +81.93% | 1 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $40 | $19.60 | +104.13% | 2 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $36 | $20.98 | +71.59% | 1 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $103 | $86.68 | +18.83% | 2 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $39.21 | -38.79% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $7 | $2.22 | +215.32% | 7 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $22 | $13.00 | +69.23% | 6 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $53 | $10.08 | +425.79% | 9 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $1.5 → $1 | $0.79 | +26.44% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $3 → $2 | $1.21 | +65.29% | 14 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $58 | $54.26 | +6.89% | 20 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $19 | $8.66 | +119.40% | 13 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $23 | $20.98 | +9.63% | 35 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $84 | $23.65 | +255.18% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $139 → $143 | $187.40 | -23.69% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $30.45 | +31.36% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $13.26 | +13.16% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $4.34 | +107.37% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $23.99 | - | 4 | Dec 4, 2017 |
Damora Therapeutics
Apr 24, 2026
Initiates: Outperform
Price Target: $40
Current: $25.50
Upside: +56.86%
Evommune
Apr 10, 2026
Reiterates: Outperform
Price Target: $48
Current: $25.00
Upside: +92.00%
Pharvaris
Apr 6, 2026
Maintains: Outperform
Price Target: $52 → $51
Current: $28.71
Upside: +77.64%
Apogee Therapeutics
Mar 3, 2026
Maintains: Sector Perform
Price Target: $83 → $82
Current: $86.49
Upside: -5.19%
Regeneron Pharmaceuticals
Mar 2, 2026
Maintains: Sector Perform
Price Target: $745 → $765
Current: $744.44
Upside: +2.76%
MoonLake Immunotherapeutics
Mar 2, 2026
Maintains: Sector Perform
Price Target: $12 → $13
Current: $16.85
Upside: -22.85%
Aardvark Therapeutics
Mar 2, 2026
Downgrades: Sector Perform
Price Target: $18 → $6
Current: $5.52
Upside: +8.70%
ACADIA Pharmaceuticals
Feb 26, 2026
Maintains: Outperform
Price Target: $31 → $30
Current: $22.30
Upside: +34.53%
Galapagos NV
Feb 25, 2026
Maintains: Sector Perform
Price Target: $32 → $33
Current: $28.55
Upside: +15.59%
Prothena Corporation
Feb 20, 2026
Maintains: Sector Perform
Price Target: $11 → $12
Current: $10.79
Upside: +11.21%
Feb 20, 2026
Maintains: Sector Perform
Price Target: $87 → $82
Current: $69.22
Upside: +18.46%
Feb 13, 2026
Maintains: Outperform
Price Target: $546 → $541
Current: $426.01
Upside: +26.99%
Feb 12, 2026
Maintains: Outperform
Price Target: $180 → $177
Current: $128.04
Upside: +38.24%
Feb 11, 2026
Maintains: Sector Perform
Price Target: $95 → $92
Current: $95.72
Upside: -3.88%
Feb 11, 2026
Maintains: Sector Perform
Price Target: $103 → $118
Current: $127.75
Upside: -7.63%
Feb 9, 2026
Maintains: Outperform
Price Target: $217 → $233
Current: $180.67
Upside: +28.96%
Jan 30, 2026
Maintains: Outperform
Price Target: $14 → $13
Current: $8.90
Upside: +46.07%
Jan 29, 2026
Maintains: Outperform
Price Target: $28 → $30
Current: $16.49
Upside: +81.93%
Jan 23, 2026
Maintains: Outperform
Price Target: $33 → $40
Current: $19.60
Upside: +104.13%
Jan 23, 2026
Maintains: Outperform
Price Target: $20 → $36
Current: $20.98
Upside: +71.59%
Dec 16, 2025
Maintains: Outperform
Price Target: $70 → $103
Current: $86.68
Upside: +18.83%
Dec 1, 2025
Downgrades: Underperform
Price Target: $24
Current: $39.21
Upside: -38.79%
Dec 1, 2025
Upgrades: Outperform
Price Target: $4 → $7
Current: $2.22
Upside: +215.32%
Nov 21, 2025
Maintains: Outperform
Price Target: $25 → $22
Current: $13.00
Upside: +69.23%
Nov 13, 2025
Maintains: Outperform
Price Target: $55 → $53
Current: $10.08
Upside: +425.79%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $1.5 → $1
Current: $0.79
Upside: +26.44%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $3 → $2
Current: $1.21
Upside: +65.29%
Nov 4, 2025
Maintains: Outperform
Price Target: $55 → $58
Current: $54.26
Upside: +6.89%
Nov 4, 2025
Maintains: Outperform
Price Target: $30 → $19
Current: $8.66
Upside: +119.40%
Jul 17, 2025
Maintains: Sector Perform
Price Target: $25 → $23
Current: $20.98
Upside: +9.63%
Apr 22, 2025
Reiterates: Outperform
Price Target: $84
Current: $23.65
Upside: +255.18%
Feb 3, 2025
Maintains: Outperform
Price Target: $139 → $143
Current: $187.40
Upside: -23.69%
Jan 28, 2025
Reiterates: Outperform
Price Target: $40
Current: $30.45
Upside: +31.36%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $13.26
Upside: +13.16%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $4.34
Upside: +107.37%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $23.99
Upside: -